In this video, health care analysts David Williamson and Max Macaluso discuss Vertex's recent tie up with two deep-pocketed members of big pharma. Although Vertex currently owns the standard of care for hepatitis C treatments, it isn't sitting on its laurels. Watch and find out what this new deal means for Vertex, its partners, and its competitors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.